{"protocolSection": {"identificationModule": {"nctId": "NCT01034111", "orgStudyIdInfo": {"id": "0431-178"}, "secondaryIdInfos": [{"id": "2009_705"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)", "officialTitle": "An Open-label Study to Assess the Safety and Tolerability of JANUVIA (Sitagliptin) in 30 Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy"}, "statusModule": {"statusVerifiedDate": "2017-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-03-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2010-10-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-10-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-12-16", "studyFirstSubmitQcDate": "2009-12-16", "studyFirstPostDateStruct": {"date": "2009-12-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-10-03", "resultsFirstSubmitQcDate": "2011-10-03", "resultsFirstPostDateStruct": {"date": "2011-11-06", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-04-28", "lastUpdatePostDateStruct": {"date": "2017-05-30", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will assess, over a 4-week treatment period, the safety and efficacy of the addition of sitagliptin to metformin in participants with type 2 diabetes mellitus (T2DM) who failed to achieve glycemic control on metformin monotherapy."}, "conditionsModule": {"conditions": ["Type 2 Diabetes"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 30, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sitagliptin", "type": "EXPERIMENTAL", "description": "Sitagliptin as add-on therapy to a stable dose of metformin", "interventionNames": ["Drug: Sitagliptin phosphate", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Sitagliptin phosphate", "description": "Sitagliptin 100 mg tablet by mouth once daily for 4 weeks.", "armGroupLabels": ["Sitagliptin"], "otherNames": ["MK-0431", "Januvia"]}, {"type": "DRUG", "name": "Metformin", "description": "Stable dose of metformin tablet(s) by mouth (at least 1000 mg/day) for 4 weeks.", "armGroupLabels": ["Sitagliptin"], "otherNames": ["Glucophage"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Safety and Tolerability of Sitagliptin After 4 Weeks of Treatment", "description": "Safety \\& tolerability were measured in terms of the # of participants with \\>=1 adverse event (AE), \\>=1 drug-related AE, \\>=1 serious AE (SAE), or discontinued treatment due to an AE. SAEs included events occurring after initiation of glycemic rescue therapy. AE is defined as any unfavorable/unintended change in structure, function, or chemistry of the body temporally associated with the use of SPONSOR's product. SAE is defined as any AE that results in death, is life-threatening, an overdose, causes or prolongs in-patient hospitalization, or considered medically significant by the investigator.", "timeFrame": "4 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Fasting Plasma Glucose at Week 4", "description": "Calculated as the mean change from baseline in fasting plasma glucose at Week 4.", "timeFrame": "Baseline and Week 4"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Participants with T2DM failing metformin monotherapy\n* Between the ages of 18 and 79\n\nExclusion Criteria:\n\n* Participants has a history of type 1 Diabetes Mellitus or ketoacidosis", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "79 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf\n\nhttp://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg tablet daily for 4 weeks as add-on therapy to a stable dose of metformin"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "30"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "30"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg tablet daily for 4 weeks as add-on therapy to a stable dose of metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "30"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "<= 40 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}]}]}, {"title": "41 to 50 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}]}]}, {"title": "51 to 60 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}]}]}, {"title": ">= 60 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "20"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "10"}]}]}]}, {"title": "Baseline Fasting Plasma Glucose", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.9", "spread": "1.5"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Safety and Tolerability of Sitagliptin After 4 Weeks of Treatment", "description": "Safety \\& tolerability were measured in terms of the # of participants with \\>=1 adverse event (AE), \\>=1 drug-related AE, \\>=1 serious AE (SAE), or discontinued treatment due to an AE. SAEs included events occurring after initiation of glycemic rescue therapy. AE is defined as any unfavorable/unintended change in structure, function, or chemistry of the body temporally associated with the use of SPONSOR's product. SAE is defined as any AE that results in death, is life-threatening, an overdose, causes or prolongs in-patient hospitalization, or considered medically significant by the investigator.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg tablet daily for 4 weeks as add-on therapy to a stable dose of metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}]}], "classes": [{"title": "At least one adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}]}]}, {"title": "At least one drug-related adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}]}]}, {"title": "At least one serious adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Discontinued treatment due to an adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose at Week 4", "description": "Calculated as the mean change from baseline in fasting plasma glucose at Week 4.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg tablet daily for 4 weeks as add-on therapy to a stable dose of metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.6", "spread": "2.2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg tablet daily for 4 weeks as add-on therapy to a stable dose of metformin", "seriousNumAffected": 0, "seriousNumAtRisk": 30, "otherNumAffected": 4, "otherNumAtRisk": 30}], "otherEvents": [{"term": "Hepatic Enzyme Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 14.0", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 30}]}, {"term": "Decreased Appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 14.0", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 30}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor shall have the opportunity to review all abstracts, drafts or proposed presentations regarding this study 60 days prior to submission for publication/presentation. Any information that the sponsor identifies as confidential should be deleted prior to submission."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck, Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Dextromethorphan", "relevance": "HIGH"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}